Frontrunner Amgen Expects US Biosimilars To ‘Shift Significantly’ With Adalimumab
Firm Prepares To Launch First Humira Biosimilar At A ‘Pivotal Time’ For The US Market
Amgen expects a significant shift in the US biosimilars landscape as Humira rivals launch next year, Chad Pettit, the firm’s executive director of marketing and global biosimilars lead, tells Generics Bulletin. The company expects to be first to market with its version of adalimumab from the end of January 2023, helping to drive long-term growth ambitions for its biosimilars business.
You may also be interested in...
A balanced policy environment that supports competition is needed to allow biosimilars to flourish in the US, according to Amgen, along with strong and transparent IP processes to underpin continuing innovation in the biologics space. Chad Pettit, the firm’s executive director of marketing and global biosimilars commercial lead, talks to Generics Bulletin about the firm’s “unique perspective” on biosimilars.
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.